

# Real Life™

**Larry Goldstein, PhD**  
Chair, CIRM Neuro Task Force  
Neuro Task Force Meeting #5  
June 20, 2023



## OUR MISSION

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world



(2007-2023)


1. Percent of Disc, Tran and Clin awards that are Neuro
2. Percent of Neuro Disc awards that progressed to Tran or Clin
3. Percent of Disc awards that are Neuro relative to disease burden – same for Tran and Clin
4. Percent of Tran and Clin awards relative to disease burden in population
5. Distribution of Neuro awards relative to geography of academic and medical research institutions

# Aspects of CIRM's R&D Neuro Portfolio (2007-2023)

1. Percent of Disc, Tran and Clin awards that are Neuro
2. Percent of Neuro Disc awards that progressed to Tran or Clin
3. Percent of Disc awards that are Neuro relative to disease burden – same for Tran and Clin
4. Percent of Tran and Clin awards relative to disease burden in population
5. Distribution of Neuro awards relative to geography of academic and medical research institutions

# CIRM's R&D Neuro Portfolio (2007-2023)

% of Total Awards




# Awards	
Neuro	Total
196	689
33	96
30	136

# CIRM's R&D Neuro Portfolio

(2007-2023)

% Funds spent in Neuro/Pillar



\$ Funds (in \$M)	
Neuro	Total
362	1.17B
204	581M
367	1.27B

# Aspects of CIRM's R&D Neuro Portfolio (2007-2023)

1. Percent of Disc, Tran and Clin awards that are Neuro
- 2. Percent of Neuro Disc awards that progressed to Tran or Clin**
3. Percent of Disc awards that are Neuro relative to disease burden – same for Tran and Clin
4. Percent of Tran and Clin awards relative to disease burden in population
5. Distribution of Neuro awards relative to geography of academic and medical research institutions

# Neuro Progression by Disease Area (2007-present)

PI	Institution	Indication	DISC-Idea	DISC-candidate	TRAN	CLIN1	CLIN2
Langston/Schuele	Parkinson Inst	Parkinson's Disease					
Schaffer	UC Berkeley	Parkinson's Disease					
Loring/Aspen	Scripps	Parkinson's Disease					
Bankiewicz	UCSF	Parkinson's Disease					
Huang	Gladstone	Alzheimer's Disease					
Schubert	Salk	Alzheimer's Disease					
Huang	UC San Diego	ALS					
Goldstein	UC San Diego	ALS					
Svendsen	Cedars Sinai	ALS					
Thompson	UC Irvine	Huntington's Disease					
Klassen/J Cyte	UC Irvine	Retinitis Pigmentosa					
Seiler	UC Irvine	Retinitis Pigmentosa					
Svendsen	Cedars Sinai	Retinitis Pigmentosa					
Humayun	USC	Macular Degeneration					
Anderson	UC Davis	Spinal Cord Injury					
Heilshorn	Stanford	Spinal Cord Injury					
Tuszynski	UC San Diego	Spinal Cord Injury					
Carmichael/Llorente	UC Los Angeles	Spinal Cord Injury					
Cummings	UC Irvine	Traumatic Brain Injury					
Steinberg	Stanford	Stroke					
Baulch/Achayra	UC Irvine	Radiation Brain injury					
Nicholas/Kriegstein	UCSF/Neurona	epilepsy					
Gleeson	UC San Diego	epilepsy					
Muotri	UC San Diego	Rett Syndrome					
Blurton-Jones	UC Irvine	Leukoencephaly					
Shi	City of Hope	Canavan Disease					
Grikscheit	CHLA	Enteric Neuropathy					
Farmer	UC Davis	Spina Bifida					

28 projects progressed:

- 15 DISC to TRAN/CLIN
- 2% of total DISC awards (689)

Indication Coding:

- Neurodegenerative
- Eye
- Neurotrauma
- Epilepsy
- Other




# Aspects of CIRM's R&D Neuro Portfolio (2007-2023)

1. Percent of Disc, Tran and Clin awards that are Neuro
2. Percent of Neuro Disc awards that progressed to Tran or Clin
- 3. Percent of Disc awards that are Neuro relative to disease burden**
4. Percent of Tran and Clin awards relative to disease burden in population
5. Distribution of Neuro awards relative to geography of academic and medical research institutions

# DISC R&D Neuro Portfolio by US Disease Burden (2007-2023)

## CIRM Funding \$M

## DALY<sup>1</sup> per 100,000



1. One disability-adjusted life year (DALY) represents the loss of the equivalent of one year of full health.

Sources: (1) CIRM portfolio data as of June 2023. (2) Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021. (3) GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet. Neurology*, 18(1), 56–87.


# Aspects of CIRM's R&D Neuro Portfolio (2007-2023)

1. Percent of Disc, Tran and Clin awards that are Neuro
2. Percent of Neuro Disc awards that progressed to Tran or Clin
3. Percent of Disc awards that are Neuro relative to disease burden
4. Percent of Tran and Clin awards relative to disease burden in population
5. Distribution of Neuro awards relative to geography of academic and medical research institutions

# TRAN R&D Neuro Portfolio by US Disease Burden (2007-2023)

## CIRM Funding \$M


## DALY<sup>1</sup> per 100,000



1. One disability-adjusted life year (DALY) represents the loss of the equivalent of one year of full health.

Sources: (1) CIRM portfolio data as of June 2023. (2) Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021. (3) GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet. Neurology*, 18(1), 56–87.

# CLIN R&D Neuro Portfolio by US Disease Burden (2007-2023)



1. One disability-adjusted life year (DALY) represents the loss of the equivalent of one year of full health.


Sources: (1) CIRM portfolio data as of June 2023. (2) Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021. (3) GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet. Neurology*, 18(1), 56–87.

# Aspects of CIRM's R&D Neuro Portfolio (2007-2023)

1. Percent of Disc, Tran and Clin awards that are Neuro
2. Percent of Neuro Disc awards that progressed to Tran or Clin
3. Percent of Disc awards that are Neuro relative to disease burden
4. Percent of Tran and Clin awards relative to disease burden in population
5. **Distribution of Neuro awards relative to geography of academic and medical research institutions**


# DISC R&D Neuro Awards by Region

(2007-2023)



As of June 5, 2023; regions as per [2020 Census](#)


# TRAN R&D Neuro Awards by Region (2007-2023)





# CLIN R&D Neuro Awards by Region

(2007-2023)



1. What percentage of \$1.5B+ does task force want to make recommendations for?
2. What percentage of \$1.5B+ should be allocated based on quality/novelty of ideas and approach as assessed by grants working group as opposed to centralized planning?
3. Are there any important areas of Neuro research that we are missing?